Figure 5.
Longitudinal 1H MRS data of the brain metabolites in the cerebellum region of the ‘rifaximin’ treated group, the ‘rifaximin + probiotics’ treated group and the group without treatment. Relative changes indicated in the graph at week 6 are calculated relative to week 0 and are indicated for metabolites whose concentrations significantly varied over time. Statistical significance: One-way ANOVA (*p < 0.05; **p < 0.01; ***p < 0.001). Note that in the cerebellum many concentrations estimated with LCModel of Asp and Ala were excluded due to their unreliability (CRLB > 30%). As this made difficult to interpret the variations of these metabolites, their evolutions are not shown. GSH at week 8 is not shown for the same reason.